177 related articles for article (PubMed ID: 10885776)
1. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
Erickson JW; Gulnik SV; Markowitz M
AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776
[No Abstract] [Full Text] [Related]
2. Salvage therapy for patients failing their current antiretroviral regimen.
Albrecht MA
AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
[No Abstract] [Full Text] [Related]
3. Cross-resistance within the protease inhibitor class.
Race E
Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
[No Abstract] [Full Text] [Related]
4. Salvage therapy: still more intuition than data.
Gilden D
GMHC Treat Issues; 1999 Jan; 13(1):6-12. PubMed ID: 11366112
[TBL] [Abstract][Full Text] [Related]
5. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
Hicks C
AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
[TBL] [Abstract][Full Text] [Related]
6. Update of the drug resistance mutations in HIV-1: 2004.
Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
[No Abstract] [Full Text] [Related]
7. Pharmacological exposure and the development of drug resistance in HIV.
Hoetelmans R
Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
[No Abstract] [Full Text] [Related]
8. HIV resistance: the new enemy.
Colvin R
Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
[TBL] [Abstract][Full Text] [Related]
9. [Human immunodeficiency virus and antiretroviral therapy resistance].
Quirós E; Torti C; Carosi G
Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
[No Abstract] [Full Text] [Related]
10. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
11. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.
Morand-Joubert L; Charpentier C; Poizat G; Chêne G; Dam E; Raguin G; Taburet AM; Girard PM; Hance AJ; Clavel F
Antivir Ther; 2006; 11(2):143-54. PubMed ID: 16640095
[TBL] [Abstract][Full Text] [Related]
12. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
[No Abstract] [Full Text] [Related]
13. Predictors of virologic response to ritonavir-boosted protease inhibitors.
Marcelin AG; Flandre P; Peytavin G; Calvez V
AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
[TBL] [Abstract][Full Text] [Related]
14. After the drugs: what's next?
Schouten JT
Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitors: resistance, resistance, resistance.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
[TBL] [Abstract][Full Text] [Related]
17. How good does your virus look in a bikini? Or, does viral fitness matter?
Martinez LJ
Res Initiat Treat Action; 1999 Oct; 5(4):15-7. PubMed ID: 11366938
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of viral fitness.
Geretti AM
J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
[TBL] [Abstract][Full Text] [Related]
19. Multi-drug resistant HIV-1.
Omrani AS; Pillay D
J Infect; 2000 Jul; 41(1):5-11. PubMed ID: 10942635
[No Abstract] [Full Text] [Related]
20. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
Walter H; Schmidt B; Rascu A; Helm M; Moschik B; Paatz C; Kurowski M; Korn K; Uberla K; Harrer T
Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]